Novacyt (NCYTL) Stock Overview

Develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. More details

NCYTL fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Earnings have declined by 70.7% per year over past 5 years

Shares are highly illiquid

Does not have a meaningful market cap (£34M)

NCYTL Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Hoth Therapeutics

100% Patient Improvement in trial puts this $16M Biotech on the radar

Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.

132

US$5.3

70.2% undervalued

Jolt_Communications Fair Value

Revenue growth

N/A

Profit Margin

30%

Future PE

20x

Share price in 2030

US$0

Novacyt S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Novacyt
Historical stock prices
Current Share Price	€0.40
52 Week High	€0.47
52 Week Low	€0.38
Beta	0.28
1 Month Change	5.24%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-12.80%

Recent updates

Shareholder Returns

	NCYTL	GB Biotechs	GB Market
7D	0%	9.0%	2.2%
1Y	n/a	9.8%	13.4%

Return vs Industry: Insufficient data to determine how NCYTL performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how NCYTL performed against the UK Market.

Price Volatility

Is NCYTL's price volatile compared to industry and market?
NCYTL volatility
NCYTL Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.1%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.8%
10% least volatile stocks in GB Market	2.4%

Stable Share Price: NCYTL's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine NCYTL's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2006	234	Lyn Rees	www.novacyt.com

Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine.

Novacyt S.A. Fundamentals Summary

How do Novacyt's earnings and revenue compare to its market cap?
NCYTL fundamental statistics
Market cap	UK£29.20m
Earnings (TTM)	-UK£28.49m
Revenue (TTM)	UK£19.45m

1.5x

P/S Ratio

-1.0x

P/E Ratio

Is NCYTL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NCYTL income statement (TTM)
Revenue	UK£19.45m
Cost of Revenue	UK£8.23m
Gross Profit	UK£11.22m
Other Expenses	UK£39.71m
Earnings	-UK£28.49m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.40
Gross Margin	57.70%
Net Profit Margin	-146.48%
Debt/Equity Ratio	0%

How did NCYTL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/10/05 02:11
End of Day Share Price	2025/09/25 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novacyt S.A. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Mathieu Jasmin	Arkeon Finance
Johann Carrier	Invest Securities
Stefan Hamill	Numis Securities Ltd.

Novacyt S.A.BATS-CHIXE:NCYTL Stock Report